Maria G Castro

List of Publications by Year
in descending order

233 papers	9,330 citations	44069 48 h-index	56724 83 g-index
250 all docs	250 docs citations	250 times ranked	11107 citing authors

#	Article	IF	Citations
1	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
2	HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression. PLoS Medicine, 2009, 6, e1000010.	8.4	310
3	Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. Journal of Neuro-Oncology, 2007, 85, 133-148.	2.9	300
4	ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Science Translational Medicine, 2016, 8, 328ra28.	12.4	212
5	Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 2013, 9, 277-291.	10.1	202
6	Acute Direct Adenoviral Vector Cytotoxicity and Chronic, but Not Acute, Inflammatory Responses Correlate with Decreased Vector-Mediated Transgene Expression in the Brain. Molecular Therapy, 2001, 3, 36-46.	8.2	171
7	IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Science Translational Medicine, 2019, 11, .	12.4	169
8	Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nature Biotechnology, 2001, 19, 582-585.	17.5	149
9	Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions. Current Gene Therapy, 2007, 7, 347-360.	2.0	144
10	Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nature Communications, 2020, 11, 5687.	12.8	142
11	Stability of Lentiviral Vector-Mediated Transgene Expression in the Brain in the Presence of Systemic Antivector Immune Responses. Human Gene Therapy, 2005, 16, 741-751.	2.7	137
12	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. Neoplasia, 2014, 16, 543-561.	5.3	131
13	Immunosuppressive Myeloid Cellsâ€™ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Molecular Therapy, 2017, 25, 232-248.	8.2	130
14	Engineering patient-specific cancer immunotherapies. Nature Biomedical Engineering, 2019, 3, 768-782.	22.5	123
15	High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano, 2019, 13, 1365-1384.	14.6	122
16	Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model. Cancer Research, 2005, 65, 7194-7204.	0.9	121
17	Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials. PLoS ONE, 2008, 3, e1983.	2.5	109
18	Interleukin-1 Mediates a Rapid Inflammatory Response After Injection of Adenoviral Vectors into the Brain. Journal of Neuroscience, 1999, 19, 1517-1523.	3.6	107

#	Article	IF	Citations
19	Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opinion on Therapeutic Targets, 2018, 22, 599-613.	3.4	103
20	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nature Communications, 2020, 11, 3811.	12.8	103
21	Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo. Molecular Therapy, 2000, 2, 330-338.	8.2	102
22	Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. Journal of Neuroimmunology, 1993, 44, 7-13.	2.3	98
23	In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. Journal of Experimental Medicine, 2006, 203, 2095-2107.	8.5	96
24	B Cells Are Critical to T-cellâ€"Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma. Neoplasia, 2011, 13, 947-IN23.	5.3	96
25	Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity. Clinical Cancer Research, 2009, 15, 4401-4414.	7.0	95
26	Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in the Brain in the Presence of an Immune Response against Adenoviruses. Journal of Virology, 2006, 80, 27-37.	3.4	89
27	Tolerance to Cardiac Allografts Via Local and Systemic Mechanisms After Adenovirus-Mediated CTLA4Ig Expression. Journal of Immunology, 2000, 164, 5258-5268.	0.8	88
28	Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain. Journal of Immunology, 2006, 176, 3566-3577.	0.8	88
29	Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20021-20026.	7.1	88
30	Prolonged Blockade of CD40-CD40 Ligand Interactions by Gene Transfer of CD40Ig Results in Long-Term Heart Allograft Survival and Donor-Specific Hyporesponsiveness, But Does Not Prevent Chronic Rejection. Journal of Immunology, 2002, 168, 1600-1609.	0.8	87
31	Treatment of Experimental Glioma by Administration of Adenoviral Vectors Expressing Fas Ligand. Human Gene Therapy, 1999, 10, 1641-1648.	2.7	86
32	Inflammatory and Anti-glioma Effects of an Adenovirus Expressing Human Soluble Fms-like Tyrosine Kinase 3 Ligand (hsFlt3L): Treatment with hsFlt3L Inhibits Intracranial Glioma Progression. Molecular Therapy, 2004, 10, 1071-1084.	8.2	86
33	Cell-Type-Specific and Regulatable Transgenesis in the Adult Brain: Adenovirus-Encoded Combined Transcriptional Targeting and Inducible Transgene Expression. Molecular Therapy, 2000, 2, 579-587.	8.2	78
34	One-year Expression From High-capacity Adenoviral Vectors in the Brains of Animals With Pre-existing Anti-adenoviral Immunity: Clinical Implications. Molecular Therapy, 2007, 15, 2154-2163.	8.2	78
35	Adenovirus-Mediated Gene Transfer of a Secreted Transforming Growth Factor-Î² Type II Receptor Inhibits Luminal Loss and Constrictive Remodeling After Coronary Angioplasty and Enhances Adventitial Collagen Deposition. Circulation, 2001, 104, 2595-2601.	1.6	76
36	Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy, 2004, 11, 721-732.	4.6	75

#	Article	IF	Citations
37	CXCR4 increases <i>in-vivo</i> glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget, 2016, 7, 83701-83719.	1.8	75
38	Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. Journal of Neurosurgery, 2007, 107, 568-577.	1.6	74
39	Gene Therapy and Targeted Toxins for Glioma. Current Gene Therapy, 2005, 5, 535-557.	2.0	71
40	Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	70
41	Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?. Current Gene Therapy, 2009, 9, 368-374.	2.0	70
42	Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-Oncology, 2008, 10, 19-31.	1.2	68
43	Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. Clinical Cancer Research, 2009, 15, 6113-6127.	7.0	68
44	Gene Therapy and Targeted Toxins for Glioma. Current Gene Therapy, 2011, 11, 155-180.	2.0	66
45	Natural Killer Cells Eradicate Galectin-1â€“Deficient Glioma in the Absence of Adaptive Immunity. Cancer Research, 2014, 74, 5079-5090.	0.9	62
46	Current state and future prospects of immunotherapy for glioma. Immunotherapy, 2018, 10, 317-339.	2.0	60
47	Recent advances and future of immunotherapy for glioblastoma. Expert Opinion on Biological Therapy, 2016, 16, 1245-1264.	3.1	57
48	Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. Oncotarget, 2016, 7, 65696-65706.	1.8	55
49	Cytotoxic immunological synapses do not restrict the action of interferon-Î³ to antigenic target cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7835-7840.	7.1	54
50	Current Approaches for Glioma Gene Therapy and Virotherapy. Frontiers in Molecular Neuroscience, 2021, 14, 621831.	2.9	54
51	Gene therapy for brain tumors: Basic developments and clinical implementation. Neuroscience Letters, 2012, 527, 71-77.	2.1	53
52	G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Science Advances, 2021, 7, eabh3243.	10.3	53
53	Adenovirus Binding to the Coxsackievirus and Adenovirus Receptor or Integrins Is Not Required To Elicit Brain Inflammation but Is Necessary To Transduce Specific Neural Cell Types. Journal of Virology, 2002, 76, 3452-3460.	3.4	49
54	Infiltrating CTLs in Human Glioblastoma Establish Immunological Synapses with Tumorigenic Cells. American Journal of Pathology, 2009, 175, 786-798.	3.8	49

#	Article	IF	Citations
55	Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety. Current Gene Therapy, 2009, 9, 409-421.	2.0	48
56	Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions. Molecular Cancer Therapeutics, 2014, 13, 3024-3036.	4.1	48
57	Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. Clinical Cancer Research, 2020, 26, 4369-4380.	7.0	48
58	Expression of Transgenes in Normal and Neoplastic Anterior Pituitary Cells Using Recombinant Adenoviruses: Long Term Expression, Cell Cycle Dependency, and Effects on Hormone Secretion*. Endocrinology, 1997, 138, 2184-2194.	2.8	47
59	Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine, 2010, 28, 3371-3378.	3.8	47
60	Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. Cell Death and Disease, 2018, 9, 1010.	6.3	47
61	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. IScience, 2020, 23, 101453.	4.1	47
62	Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics. Neoplasia, 2012, 14, 757-IN26.	5.3	46
63	Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Research, 2017, 77, 227-233.	0.9	46
64	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine, 2020, 12, .	12.4	46
65	T Cells' Immunological Synapses Induce Polarization of Brain Astrocytes In Vivo and In Vitro: A Novel Astrocyte Response Mechanism to Cellular Injury. PLoS ONE, 2008, 3, e2977.	2.5	46
66	Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors. Current Topics in Medicinal Chemistry, 2005, 5, 1151-1170.	2.1	44
67	Effective High-Capacity Gutless Adenoviral Vectors Mediate Transgene Expression in Human Glioma Cells. Molecular Therapy, 2006, 14, 371-381.	8.2	44
68	Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opinion on Biological Therapy, 2014, 14, 1241-1257.	3.1	44
69	Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumorâ€“induced Behavioral Deficits. Molecular Therapy, 2008, 16, 682-690.	8.2	43
70	Systemic Delivery of an Adjuvant CXCR4â€“CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. ACS Nano, 2022, 16, 8729-8750.	14.6	43
71	Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen. Molecular Therapy, 2011, 19, 1793-1801.	8.2	42
72	Regulated, Adenovirus-Mediated Delivery of Tyrosine Hydroxylase Suppresses Growth of Estrogen-Induced Pituitary Prolactinomas. Molecular Therapy, 2001, 4, 593-602.	8.2	41

#	Article	IF	Citations
73	Development of a Novel Helper-Dependent Adenovirus-Epstein-Barr Virus Hybrid System for the Stable Transformation of Mammalian Cells. Journal of Virology, 2004, 78, 6556-6566.	3.4	41
74	ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Molecular and Cellular Oncology, 2016, 3, e1167158.	0.7	41
75	Survival and Proliferation of Neural Progenitorâ€“Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism. Clinical Cancer Research, 2017, 23, 1250-1262.	7.0	41
76	Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Therapy, 2001, 8, 589-598.	4.6	40
77	Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-Oncology, 2007, 9, 245-258.	1.2	40
78	Overview of current immunotherapeutic strategies for glioma. Immunotherapy, 2015, 7, 1073-1104.	2.0	40
79	Adenovirus-Mediated Gene Transfer of Transforming Growth Factor-Î² ₃ , but Not Transforming Growth Factor-Î² ₁ , Inhibits Constrictive Remodeling and Reduces Luminal Loss After Coronary Angioplasty. Circulation, 2003, 108, 2819-2825.	1.6	39
80	Immunization Against the Transgene but not the TetON Switch Reduces Expression From Gutless Adenoviral Vectors in the Brain. Molecular Therapy, 2008, 16, 343-351.	8.2	38
81	Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. OncoImmunology, 2018, 7, e1408750.	4.6	38
82	Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discovery Medicine, 2010, 10, 293-304.	0.5	38
83	A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics. Journal of Virology, 2010, 84, 6007-6017.	3.4	37
84	Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clinical Immunology, 2018, 189, 34-42.	3.2	37
85	Towards Global and Long-Term Neurological Gene Therapy: Unexpected Transgene Dependent, High-Level, and Widespread Distribution of HSV-1 Thymidine Kinase throughout the CNS. Molecular Therapy, 2001, 4, 490-498.	8.2	35
86	In Vivo Polarization of IFN-Î³ at Kupfer and Non-Kupfer Immunological Synapses during the Clearance of Virally Infected Brain Cells. Journal of Immunology, 2008, 180, 1344-1352.	0.8	35
87	Engineering the Brain Tumor Microenvironment Enhances the Efficacy of Dendritic Cell Vaccination: Implications for Clinical Trial Design. Clinical Cancer Research, 2011, 17, 4705-4718.	7.0	35
88	Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. Neuro-Oncology, 2020, 22, 806-818.	1.2	34
89	Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood, 2003, 101, 3325-3333.	1.4	33
90	Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Molecular Cancer Therapeutics, 2008, 7, 439-448.	4.1	33

#	Article	IF	Citations
91	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-ÎºB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. Neurotherapeutics, 2012, 9, 827-843.	4.4	33
92	Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma. Journal of Visualized Experiments, 2015, , .	0.3	33
93	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology, 2021, 12, 680021.	3.5	33
94	Preclinical Characterization of Signal Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and Metastatic Brain Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 458-469.	2.5	32
95	Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models. Clinical Cancer Research, 2014, 20, 1555-1565.	7.0	32
96	A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. Lab on A Chip, 2019, 19, 1162-1173.	6.0	32
97	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Reports, 2022, 38, 110216.	6.4	32
98	High-Capacity Adenovirus Vector-Mediated Anti-Glioma Gene Therapy in the Presence of Systemic Antiadenovirus Immunity. Journal of Virology, 2008, 82, 4680-4684.	3.4	31
99	Human Flt3L Generates Dendritic Cells from Canine Peripheral Blood Precursors: Implications for a Dog Glioma Clinical Trial. PLoS ONE, 2010, 5, e11074.	2.5	30
100	Long-Term Transgene Expression within the Anterior Pituitary Glandin Situ: Impact on Circulating Hormone Levels, Cellular and Antibody-Mediated Immune Responses1. Endocrinology, 2001, 142, 464-476.	2.8	29
101	Switching On and Off Transgene Expression within Lactotrophic Cells in the Anterior Pituitary Glandin Vivo1. Endocrinology, 2001, 142, 2521-2532.	2.8	29
102	Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biology, 2006, 2, 309-322.	1.6	29
103	Gene Transfer into Rat Brain Using Adenoviral Vectors. Current Protocols in Neuroscience, 2010, 50, Unit 4.24.	2.6	29
104	Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nature Communications, 2022, 13, .	12.8	29
105	Efficacy of nonviral gene transfer in the canine brain. Journal of Neurosurgery, 2007, 107, 136-144.	1.6	28
106	Natural killer cells require monocytic Gr-1⁺/CD11b⁺myeloid cells to eradicate orthotopically engrafted glioma cells. OncoImmunology, 2016, 5, e1163461.	4.6	28
107	Adenovirus vectorâ€“mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Therapy, 2002, 9, 897-907.	4.6	27
108	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clinical Immunology, 2018, 189, 43-51.	3.2	27

#	Article	IF	Citations
109	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Frontiers in Oncology, 2021, 11, 703764.	2.8	27
110	Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 1777.	4.1	26
111	Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells. Molecular and Cellular Endocrinology, 1998, 139, 199-207.	3.2	24
112	Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicology and Applied Pharmacology, 2013, 268, 318-330.	2.8	24
113	Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!. Clinical Cancer Research, 2014, 20, 5147-5149.	7.0	24
114	Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics, 2021, 11, 1295-1309.	10.0	24
115	Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. Molecular Cancer Therapeutics, 2020, 19, 1550-1561.	4.1	22
116	Progress and challenges in viral vector-mediated gene transfer to the brain. Current Opinion in Molecular Therapeutics, 2002, 4, 359-71.	2.8	22
117	Gene Therapy for Liver Transplantation Using Adenoviral Vectors: CD40â€“CD154 Blockade by Gene Transfer of CD40Ig Protects Rat Livers from Cold Ischemia and Reperfusion Injury. Molecular Therapy, 2004, 9, 38-45.	8.2	21
118	Human gene therapy and imaging in neurological diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, S358-S383.	6.4	21
119	Safety Profile of Gutless Adenovirus Vectors Delivered into the Normal Brain Parenchyma: Implications for a Glioma Phase 1 Clinical Trial. Human Gene Therapy Methods, 2012, 23, 271-284.	2.1	21
120	Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. Journal of Virology, 2017, 91, .	3.4	21
121	Recent advances in the pharmacology of neurological gene therapy. Current Opinion in Pharmacology, 2004, 4, 91-97.	3.5	20
122	Immunology of Neurological Gene Therapy: How T Cells Modulate Viral Vector-Mediated Therapeutic Transgene Expression Through Immunological Synapses. Neurotherapeutics, 2007, 4, 715-724.	4.4	20
123	Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14443-14448.	7.1	20
124	Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors. Current Protocols in Neuroscience, 2000, 13, Unit 4.23.	2.6	19
125	Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials. Neurologia Medico-Chirurgica, 2013, 53, 741-754.	2.2	19
126	Microtubule targeting agents in glioma. Translational Cancer Research, 2016, 5, S54-S60.	1.0	19

#	Article	IF	Citations
127	Pro-opiomelanocortin and pro-vasopressin converting enzyme in pituitary secretory vesicles. Biochimie, 1988, 70, 11-16.	2.6	18
128	Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors. Current Protocols in Neuroscience, 2008, 45, Unit 4.23.	2.6	18
129	Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma. Clinical Cancer Research, 2020, 26, 4080-4092.	7.0	18
130	T lymphocytes as dynamic regulators of glioma pathobiology. Neuro-Oncology, 2022, 24, 1647-1657.	1.2	18
131	CD20, CD3, and CD40 Ligand Microclusters Segregate Three-Dimensionally In Vivo at B-Cell-T-Cell Immunological Synapses after Viral Immunity in Primate Brain. Journal of Virology, 2008, 82, 9978-9993.	3.4	17
132	Immune-mediated Loss of Transgene Expression From Virally Transduced Brain Cells Is Irreversible, Mediated by IFNÎ³, Perforin, and TNFÎ±, and due to the Elimination of Transduced Cells. Molecular Therapy, 2012, 20, 808-819.	8.2	17
133	Single vs. combination immunotherapeutic strategies for glioma. Expert Opinion on Biological Therapy, 2017, 17, 543-554.	3.1	17
134	Genetic engineering within the adult brain: Implications for molecular approaches to behavioral neuroscience. Physiology and Behavior, 2001, 73, 833-839.	2.1	16
135	Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities. International Journal of Molecular Sciences, 2020, 21, 9654.	4.1	16
136	Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 305-317.	3.1	16
137	Effect of the Corticotrophin Releasing Hormone Precursor on Interleukin-6 Release by Human Mononuclear Cells. Clinical Immunology and Immunopathology, 1997, 85, 35-39.	2.0	15
138	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 659-684.	4.1	15
139	First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.. Journal of Clinical Oncology, 2019, 37, 2019-2019.	1.6	15
140	Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours. Trends in Endocrinology and Metabolism, 2001, 12, 58-64.	7.1	14
141	ADENOVIRAL-MEDIATED GENE TRANSFERINTO THE CANINE BRAIN IN VIVO. Neurosurgery, 2007, 60, 167-178.	1.1	14
142	Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. Journal of Visualized Experiments, 2015, , .	0.3	14
143	Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. Neuro-Oncology, 2020, 22, 195-206.	1.2	14
144	A novel miR1983-TLR7-IFNÎ² circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. OncoImmunology, 2021, 10, 1939601.	4.6	14

#	Article	IF	Citations
145	Expression of Biologically Active Procorticotrophin-Releasing Hormone (proCRH) in Stably Transfected CHO-K1 Cells: Characterization of Nuclear proCRH. Journal of Neuroendocrinology, 1995, 7, 263-272.	2.6	13
146	Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium. Metabolic Brain Disease, 1999, 14, 205-221.	2.9	13
147	Intrapituitary Adenoviral Administration of 7B2 Can Extend Life Span and Reverse Endocrinological Deficiencies in 7B2 Null Mice. Endocrinology, 2002, 143, 2314-2323.	2.8	12
148	Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1713-1732.	2.5	12
149	Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neuro-Oncology Advances, 2020, 2, vdaa042.	0.7	12
150	Long-Term Transgene Expression within the Anterior Pituitary Gland in Situ: Impact on Circulating Hormone Levels, Cellular and Antibody-Mediated Immune Responses. Endocrinology, 2001, 142, 464-476.	2.8	12
151	Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM. PLoS ONE, 2014, 9, e96318.	2.5	12
152	Reversibility of glioma stem cellsâ€™ phenotypes explains their complex <i>in vitro</i> and <i>in vivo</i> behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool. Oncotarget, 2016, 7, 63020-63041.	1.8	12
153	Adenovirus expression of IL-1 and NF-ÎºB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. Molecular Therapy, 2003, 8, 400-411.	8.2	11
154	Generation of a Recombinant Herpes Simplex Virus TypeÂ1 Expressing the Rat Corticotropin- Releasing Hormone Precursor: Endoproteolytic Processing, Intracellular Targeting and Biological Activity. Neuroendocrinology, 1999, 70, 439-450.	2.5	10
155	Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics, 2014, 11, 623-635.	4.4	10
156	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Frontiers in Oncology, 2021, 11, 631037.	2.8	10
157	Chapter 33 Gene therapy for inherited neurological disorders: Towards therapeutic intervention in the Lesch-Nyhan syndrome. Progress in Brain Research, 1998, 117, 485-501.	1.4	9
158	Gene Therapy for Pituitary Tumors. Current Gene Therapy, 2005, 5, 559-572.	2.0	9
159	Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 729-738.	1.7	9
160	Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts. Neuromethods, 2012, 77, 229-243.	0.3	9
161	Effectiveness and Preclinical Safety Profile of Doxycycline to Be Used â€œOff-Labelâ€•to Induce Therapeutic Transgene Expression in a Phase I Clinical Trial for Glioma. Human Gene Therapy Clinical Development, 2013, 24, 116-126.	3.1	9
162	Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system. Methods in Enzymology, 2020, 632, 369-388.	1.0	9

#	Article	IF	Citations
163	Regulated Expression of Adenoviral Vectors-Based Gene Therapies. , 2008, 434, 239-266.		9
164	Procorticotrophin releasing hormone is endoproteolytically processed by the prohormone convertase PC2 but not by PC1 within stably transfected CHO-K1 cells. Biochemical Society Transactions, 1996, 24, 497S-497S.	3.4	8
165	Use of Recombinant Adenovirus for Gene Transfer into the Rat Brain: Evaluation of Gene Transfer Efficiency, Toxicity, and Inflammatory and Immune Reactions. , 2003, 76, 113-134.		8
166	Gene therapy for pituitary tumors: from preclinical models to clinical implementation. Frontiers in Neuroendocrinology, 2003, 24, 62-77.	5.2	8
167	Virus Vectors for use in the Central Nervous System. International Review of Neurobiology, 2003, 55, 3-64.	2.0	8
168	The long and winding roadâ€"gene therapy for glioma. Nature Reviews Neurology, 2013, 9, 609-610.	10.1	8
169	Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy. OncoImmunology, 2014, 3, e965573.	4.6	8
170	Marmosets as a preclinical model for testing â€œoff-labelâ€•use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Molecular Therapy - Methods and Clinical Development, 2014, 1, 10.	4.1	8
171	Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods in Molecular Biology, 2016, 1382, 467-482.	0.9	8
172	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Neuro-Oncology, 2018, 20, 1356-1367.	1.2	8
173	Targeting gliomas with STAT3-silencing nanoparticles. Molecular and Cellular Oncology, 2021, 8, 1870647.	0.7	8
174	Immune Regulation of Transgene Expression in the Brain: B Cells Regulate an Early Phase of Elimination of Transgene Expression from Adenoviral Vectors. Viral Immunology, 2006, 19, 508-517.	1.3	7
175	Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn â€œOnâ€•Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Human Gene Therapy Methods, 2016, 27, 98-111.	2.1	7
176	Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion. Journal of Visualized Experiments, 2020, , .	0.3	7
177	Switching On and Off Transgene Expression within Lactotrophic Cells in the Anterior Pituitary Gland in Vivo. Endocrinology, 2001, 142, 2521-2532.	2.8	7
178	Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas. Oncotarget, 2020, 11, 4607-4612.	1.8	7
179	An Optimized Protocol for InÂVivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model. STAR Protocols, 2020, 1, 100044.	1.2	6
180	CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics, 2021, 18, 1980-1994.	4.4	6

#	Article	IF	Citations
181	Expression of Transgenes in Normal and Neoplastic Anterior Pituitary Cells Using Recombinant Adenoviruses: Long Term Expression, Cell Cycle Dependency, and Effects on Hormone Secretion. Endocrinology, 1997, 138, 2184-2194.	2.8	6
182	The Value of EGFRvIII as the Target for Glioma Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 42-50.	3.8	5
183	Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Methods in Enzymology, 2020, 632, 215-228.	1.0	5
184	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. Vaccines, 2021, 9, 1106.	4.4	5
185	Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography. Journal of Visualized Experiments, 2020, , .	0.3	5
186	Recent developments in gene therapy: applications for the treatment of pituitary tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 431-449.	4.7	4
187	Gene therapy for the treatment of pituitary tumors. Expert Review of Endocrinology and Metabolism, 2009, 4, 359-370.	2.4	4
188	There Must Be a Way Out of Here: Identifying a Safe and Efficient Combination of Promoter, Transgene, and Vector Backbone for Gene Therapy of Neurological Disease. Molecular Therapy, 2014, 22, 246-247.	8.2	4
189	Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. Journal of Visualized Experiments, 2018, , .	0.3	4
190	Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. Journal of Visualized Experiments, 2019, , .	0.3	4
191	ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM. Neuro-Oncology, 2019, 21, vi11-vi11.	1.2	4
192	Genetically Engineered Mouse Model of Brainstem High-Grade Glioma. STAR Protocols, 2020, 1, 100165.	1.2	4
193	Intrapituitary Adenoviral Administration of 7B2 Can Extend Life Span and Reverse Endocrinological Deficiencies in 7B2 Null Mice. Endocrinology, 2002, 143, 2314-2323.	2.8	4
194	Identification and Visualization of CD8+ T Cell Mediated IFN-Î³ Signaling in Target Cells during an Antiviral Immune Response in the Brain. PLoS ONE, 2011, 6, e23523.	2.5	4
195	Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Current Opinion in Molecular Therapeutics, 2009, 11, 481-4.	2.8	4
196	Effect of caveolin-1 on Stat3-ptyr705 levels in breast and lung carcinoma cells. Biochemistry and Cell Biology, 2019, 97, 638-646.	2.0	2
197	Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. Methods in Enzymology, 2020, 631, 91-106.	1.0	2
198	Nuclear localisation of corticotrophin releasing hormone (CRH) in transfected CHO-K1 cells. Biochemical Society Transactions, 1993, 21, 318S-318S.	3.4	1

#	Article	IF	Citations
199	Application of Synthetic Tumor-Specific Promoters Responsive to the Tumor Microenvironment. Methods in Molecular Biology, 2017, 1651, 213-227.	0.9	1
200	GENE-34. MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING Acvr1 G328V. Neuro-Oncology, 2018, 20, vi110-vi111.	1.2	1
201	GENE-35. IDH1-R132H INDUCES AN EPIGENETIC REPROGRAMMING IN GLIOMA IMPACTING MEDIAN SURVIVAL, DNA-DAMAGE RESPONSE AND RADIO-SENSITIVITY. Neuro-Oncology, 2018, 20, vi111-vi111.	1.2	1
202	CSIG-08. DYNAMICS OF GLIOMA GROWTH: SELF-ORGANIZATION GUIDES THE PATTERNING OF THE EXTRACELLULAR MATRIX AND REGULATES TUMOR PROGRESSION. Neuro-Oncology, 2018, 20, vi44-vi44.	1.2	1
203	TMIC-62. FYN, AN EFFECTOR OF ONCOGENIC RECEPTOR TYROSINE KINASES SIGNALING IN GLIOBLASTOMA, INHIBITS ANTI-GLIOMA IMMUNE RESPONSES: IMPLICATIONS FOR IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, vi261-vi261.	1.2	1
204	Cell Type Specific and Inducible Transgenesis in the Anterior Pituitary Gland. Growth Hormone, 2001, , 233-256.	0.2	1
205	HMGB1 Mediates Endogenous TLR2 Activation And Brain Tumor Regression.. FASEB Journal, 2008, 22, 515-515.	0.5	1
206	Editorial: Targeting Neuroinflammation in Central Nervous System Disorders: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology, 2021, 12, 771610.	3.5	1
207	Murine brain tumor microenvironment immunophenotyping using mass cytometry. STAR Protocols, 2022, 3, 101357.	1.2	1
208	Gene Therapy for Pituitary Tumors. , 2003, 13, 351-357.		0
209	Molecular Neurosurgery in the Pituitary Gland. , 2005, 18, 580-623.		0
210	Viral gene therapy for central nervous system diseases. , 2008, , 424-434.		0
211	Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 125-125.	1.9	0
212	GENT-53. SELF-ORGANIZATION OF GLIOMAS: GENETIC RODENT MODELS, GENOMIC NETWORKS, AND MATHEMATICAL MODELING. Neuro-Oncology, 2016, 18, vi85-vi85.	1.2	0
213	PDCT-03. CLINICALLY INTEGRATED SEQUENCING IN THE MANAGEMENT OF CHILDREN WITH HIGH-RISK BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi145-vi146.	1.2	0
214	ANGI-10. GENETIC DOWN REGULATION OF CXCR4 IN GLIOMA CELLS REDUCES INVASION, REDUCES TUMOR PROGRESSION, AND INCREASES SENSITIVITY TO RADIATION. Neuro-Oncology, 2016, 18, vi17-vi17.	1.2	0
215	Viral Gene Therapy for Central Nervous System Diseases. , 2016, , 519-544.		0
216	IMMU-58. IDH1 MUTATION REGULATES MYELOID CELLS MEDIATED IMMUNOSUPPRESSION IN GLIOMA. Neuro-Oncology, 2017, 19, vi125-vi126.	1.2	0

#	Article	IF	Citations
217	IMMU-61. INHIBITION OF MUTANT IDH1 WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY ELICITING IMMUNOLOGICAL MEMORY AND IMPROVING OVERALL SURVIVAL. Neuro-Oncology, 2018, 20, vi135-vi135.	1.2	0
218	HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION. Neuro-Oncology, 2019, 21, ii88-ii88.	1.2	0
219	EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. Neuro-Oncology, 2019, 21, vi92-vi92.	1.2	0
220	TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS. Neuro-Oncology, 2019, 21, vi260-vi260.	1.2	0
221	TMIC-35. IDH1 MUTATION IN GLIOMA REPROGRAMS EARLY MYELOID DIFFERENTIATION IN THE BONE MARROW (BM) TO PRODUCE NON-IMUNESUPPRESSIVE NEUTROPHILS. Neuro-Oncology, 2019, 21, vi255-vi255.	1.2	0
222	Transient Transgenesis in The Endocrine System: Viral Vectors for Gene Delivery. Growth Hormone, 2001, , 195-232.	0.2	0
223	In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. Journal of Cell Biology, 2006, 174, i10-i10.	5.2	0
224	Depletion of CD25+ T cells inhibits CD8+ T cells clonal expansion and glioblastoma multiforme regression.. FASEB Journal, 2008, 22, 514-514.	0.5	0
225	Immunotherapies for Brain Cancer: From Preclinical Models to Human Trials. Tumors of the Central Nervous System, 2014, , 239-251.	0.1	0
226	Therapeutic implications of perivascular invasion in the context of high-density brain microvascular networks: A study on recursive pattern formation in malignant glioma.. Journal of Clinical Oncology, 2014, 32, 2057-2057.	1.6	0
227	Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models. Neuromethods, 2015, , 341-354.	0.3	0
228	IMG-12. CHARACTERISATION OF MODELS OF <i>H3F3A</i>_G34R/V MUTANT PAEDIATRIC GLIOBLASTOMA <i>IN VIVO</i> USING MAGNETIC RESONANCE IMAGING. Neuro-Oncology, 2020, 22, iii357-iii357.	1.2	0
229	TAMI-52. G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS, REVERSES THE MYELOID CELLSâ€™-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT. Neuro-Oncology, 2020, 22, ii224-ii224.	1.2	0
230	CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, ii16-ii16.	1.2	0
231	The Brain as a Target for Gene Therapy. , 0, , 153-165.		0
232	Immune Responses to Viral Vectors Injected Systemically or into the CNS. , 0, , 167-179.		0
233	IMMU-12. Exploring and modulating the tumour immune microenvironment to facilitate the selection of immunotherapies for paediatric-type diffuse high-grade glioma. Neuro-Oncology, 2022, 24, i83-i84.	1.2	0